(4-octanoylphenyl)Methyl-Triphenylphosphanium;Bromide置于甲醇,Sodium Tetrahydroborate,水,Potassium Carbonate,三氟乙酸体系中,用 四氢呋喃,二氯甲烷,N,N-二甲基甲酰胺 用作溶剂,5.0~75.0 °C,101.33 Kpa 条件下,反应生成2-氨基-2-[2-(4-辛基苯基)乙基]-1,3-丙二醇 参考文献: Intermediate Compounds And Process For The Preparation Of Fingolimod[fr] Composés Intermédiaires Et Procédé De Préparation De Fingolimod 标题: Intermediate Compounds And Process For The Preparation Of Fingolimod[fr] Composés Intermédiaires Et Procédé De Préparation De Fingolimod
专利号:US-2024287520-A1 优先权日:2021-06-30 标题:Method for synthesis of linkage modified oligomeric compounds 发明人:RODRIGUEZ ANDREW A 权利人:IONIS PHARMACEUTICALS INC 摘要:The present disclosure provides methods of synthesizing modified oligonucletodies and oligomeric compounds (including oligomeric compounds that are antisense agents or portions thereof) comprising a modified oligonucleotide having at least one modified internucleoside linking group. In certain embodiments, the present disclosure provides stabilized formulations of certain sulfonyl azides for use in the synthesis of olignonucleotides comprising one or more sulfonyl phosphoramidate linkages. Some embodiments provide stabilized compositions of high energy reagents that may be used in the synthesis of modified oligonucleotides, allowing for safe process scale preparation thereof.
专利号:WO-2012150292-A1 优先权日:2011-05-03 标题:Stereoselective synthesis of cis-4-methylsphingosine and derivatives thereof 发明人:ARENZ CHRISTOPH; PROKSCH DENNY 权利人:UNIV BERLIN HUMBOLDT; ARENZ CHRISTOPH; PROKSCH DENNY 摘要:The invention provides for synthesis of a (S-R) dihydroxy-amino-methylalkylene characterized by the general formula I, or its R-S diastereomer, wherein R1 is CH2OH or CH2-CH2OH, and R2 is C2 to C20 alkyl, whereby a compound characterized by the general formula II, with R3, R4 and R5 being protecting groups for amino and hydroxyl functions, respectively, is used as a starting material. The invention further provides novel intermediates for syntheses of, and analogues to, cis-4-methylsphingosine.
专利号:US-2025206743-A1 优先权日:2022-03-25 标 题:Tyk2 inhibitor synthesis and intermediates thereof 发明人:MASSE CRAIG E; PHADKE AVINASH S; LAWSON JON P; LEVY STUART; YANG XIAOWEI; WU GUISHENG; FAN SHUFENG 权利人:TAKEDA PHARMACEUTICALS CO 摘要:Described herein are methods of synthesis of a tyrosine-protein kinase 2 (TYK2) inhibitor and to intermediate compounds of the synthesis and methods of making the intermediates. Also provided are pharmaceutically acceptable compositions including compounds prepared by the synthetic method and methods of treating disorders using the same.
专利号:US-11649285-B2 优先权日:2016-08-03 标题 :Identification of VSIG3/VISTA as a novel immune checkpoint and use thereof for immunotherapy 发明人:KALABOKIS VASSILIOS; WANG JINGHUA; WU GUOPING; BAZAN JOSE FERNANDO; VALLEY CHRISTOPHER CARLIN 权利人:BIO TECHNE CORP 摘要:The ligand for VISTA is identified (VSIG3) as well as the use of this ligand and receptor interaction in the identification or synthesis of a VSIG3 agonist or antagonist compounds, preferably antibodies, polypeptides and fusion proteins which agonize or antagonize the effects of VSIG3 and/or VISTA and/or the VSIG3/VISTA interaction. These antagonists may be used to suppress VSIG3/VISTA's suppressive effects on T cell immunity, and more particularly used in the treatment of cancer, or infectious disease. These agonist compounds may be used to potentiate or enhance VSIG3/VISTA's suppressive effects on T cell immunity and thereby suppress T cell immunity, such as in the treatment of autoimmunity, allergy or inflammatory conditions. Screening assays for identifying these agonists and antagonist compounds are also provided.
专利号:US-2022251128-A1 优先权日:2019-05-17 标 题:Synthesis of oligomeric compounds comprising phosphorothioate diester and phosphodiester linkages 发明人:MCPHERSON ANDREW K; RODRIGUEZ ANDREW A; CAPALDI DANIEL C 权利人:IONIS PHARMACEUTICALS INC 摘要:The present disclosure provides methods for synthesizing oligomeric compounds having at least one phosphorothioate diester linkage and at least one phosphate diester internucleoside linkage. In certain embodiments, the present disclosure provides oxidation reagents that produce low amounts of unwanted phosphate diester impurities in oligomeric compounds having at least one phosphorothioate diester linkage and at least one phosphate diester internucleoside linkage.
专利号:US-10865163-B2 优先权日:2017-12-20 标题:Carbon dioxide as a directing group for C—H functionalization reactions involving Lewis basic amines, alcohols, thiols, and phosphines for the synthesis of compounds 发明人:YOUNG MICHAEL C; KAPOOR MOHIT 权利人:UNIV TOLEDO 摘要:Methods of synthesizing compounds using CO 2 as a directing group for C—H functionalization, and compounds made thereby, are described.
1: Ward MD, Jones DE, Goldman MD. Overview and safety of fingolimod hydrochloride use in patients with multiple sclerosis. Expert Opin Drug Saf. 2014 Jul;13(7):989-98. doi: 10.1517/14740338.2014.920820. Review. doi: 10.1185/03007995.2015.1067191. Epub 2015 Aug 20. Review. English, Spanish. Outcomes of switching directly to oral fingolimod from injectable therapies: Results of the randomized, open-label, multicenter, Evaluate Patient OutComes (EPOC) study in relapsing multiple sclerosis. Mult Scler Relat Disord. 2014 Sep;3(5):607-19. doi: 10.1016/j.msard.2014.06.005. Epub 2014 Jul 4. doi: 10.3109/00207454.2014.969839. Epub 2014 Oct 29. 6: Camm J, Hla T, Bakshi R, Brinkmann V. Cardiac and vascular effects of fingolimod: mechanistic basis and clinical implications. Am Heart J. 2014 Nov;168(5):632-44. doi: 10.1016/j.ahj.2014.06.028. Epub 2014 Jul 11. Review. doi: 10.1212/WNL.0000000000000137. Epub 2014 Jan 24. 8: Francis G, Kappos L, O'Connor P, Collins W, Tang D, Mercier F, Cohen JA. Temporal profile of lymphocyte counts and relationship with infections with fingolimod therapy. Mult Scler. 2014 Apr;20(4):471-80. doi: 10.1177/1352458513500551. Epub 2013 Aug 15. doi: 10.1007/s40265-014-0264-y. Review. doi: 10.1111/cns.12283. Review.
合成参考文献
参考文献:10.1038/nrneurol.2011.105 摘要:Hohlfeld R. Multiple sclerosis: Cladribine--a contentious therapeutic contender for MS. Nat Rev Neurol. 2011 Jul 12;7(8):425–7. doi: 10.1038/nrneurol.2011.105. 摘要:Fingolimod. Prescrire Int. 2011 Jul;20(118):173–4, 176. 摘要:Berger JR. Functional improvement and symptom management in multiple sclerosis: clinical efficacy of current therapies. Am J Manag Care. 2011 May;17 Suppl 5 Improving():S146–53. 参考文献:10.1182/blood-2011-01-331447 摘要:Liao A, Broeg K, Fox T, Tan SF, Watters R, Shah MV, Zhang LQ, Li Y, Ryland L, Yang J, Aliaga C, Dewey A, Rogers A, Loughran K, Hirsch L, Jarbadan NR, Baab KT, Liao J, Wang HG, Kester M, Desai D, Amin S, Loughran TP, Liu X. Therapeutic efficacy of FTY720 in a rat model of NK-cell leukemia. Blood. 2011 Sep 08;118(10):2793–800. 参考文献:10.1158/1078-0432.ccr-05-0447 摘要:Lee TK, Man K, Ho JW, Wang XH, Poon RT, Xu Y, Ng KT, Chu AC, Sun CK, Ng IO, Sun HC, Tang ZY, Xu R, Fan ST. FTY720: a promising agent for treatment of metastatic hepatocellular carcinoma. Clin Cancer Res. 2005 Dec 01;11(23):8458–66. doi: 10.1158/1078-0432.ccr-05-0447.